Our website is made possible by displaying non-intrusive online advertisements to our visitors.
Please consider supporting us by disabling or pausing your ad blocker.
The study said the side effects included "pain, feeling feverish, chills, muscle ache, headache, and malaise." That doesn't sound minor, especially when you see that participants were given a gram of acetaminophen every six hours for 24 hours after the injection of the vaccine to reduce fever, headaches, or muscle aches. Of course, given a choice between getting COVID-19 or dealing with a headache and a little fever, most people would gladly choose the latter. However, the fact that the side effects were largely glossed over made some wonder whether researchers are being overly optimistic about the vaccine's outcome.
To be fair, other recent COVID-19 vaccine candidates have shown similar side effects. Nearly all phase 2 test subjects given mRNA-1273, a candidate from Moderna (NASDAQ:MRNA), exhibited fatigue, fever, muscle aches, and headache.
Another, arguably larger reason for the drop in AstraZeneca's stock is that the pharmaceutical company is competing against so many other vaccine candidates. Partners BioNTech (NASDAQ:BNTX) and Pfizer (NYSE:PFE), for instance, also announced phase 1/2 clinical results for their vaccine candidate on Monday, though they did so via a preprint (without peer review) rather than in a peer-reviewed journal. Moderna's most recent phase 1/2 results came out last week in a New England Journal of Medicine report.
Still a good stock, with or without a vaccine
Vaccines normally take up to 10 to 15 years to produce, not months. Things are rushing forward at light speed because of the worldwide necessity for a coronavirus vaccine, but it's equally possible that multiple candidates will be successful or that none of them will work in the real world. Despite our best efforts, we still don't have vaccines for malaria, HIV, or tuberculosis.
Another potential concern is that while AZD1222 has been shown to produce antibodies, it hasn't been proven yet whether those antibodies will prevent the virus from hitting healthy cells -- or, if so, for how long. The vaccine works by mimicking the spike protein used by COVID-19 to infect cells. The hope is that after being vaccinated, the body's immune system will recognize the spike protein and swiftly mount its defense.
More encouraging, perhaps, is that the vaccine elicited a T-cell response, which should stimulate the immune system to attack cells infected by the virus.
I cant denied that Malaysia glove sector monopoly the glove market in the world, exporting more than 65% of gloves compared to usage... it is true... even shark earn money from gloves counter, they might loss making in other counter,,, UK down,,,us also down... they need the money to save their own counter also ler... and government of Malaysia can't do much ...
everyone gt their own choice.... but I join in after the price is stable... at least not now.... ride with the wave is better than fighting the phenomenon...
and Malaysia counter is based on goreng....unless some group is pumping nin money to push up the share price...if not small retailer will afraid and sell low...
winson erm mayb we r in different view la, for me n terrence i think both of us r more on fundamental, we do research , n from ur side is more on news, like refer those analyst , bt erm i do agree vaccine news will impact on glove for temporary, bt it jz news , for the long run it will still rely on the qr earning n etc
if those shark not pushing the price to the top... how can they lure small retailer to get in and keep on support the ceiling..? now is economic downtrend everywhere... if the overall market performance is good... these sure will upup...
vaccine for have any impact for glove ler... even there is vaccine... the demand for gloves will still remain... now gloves and mask has already become the new normal for everyone...
@Winson if u based on share price to invest I tell u..u just a kid ;) How come Nestle share price can go over Rm 100? Common sense pls and for those who say supermax overvalued!! Hello ! wake up? Do u think supermax upcoming QR PAT will be maintain 400m or below 400m?
kawan.... ur comparing nestle with glove.... nestle total share capital is only 32b and superman share capital is 24m... is the total capital affect the unit share price... unit share reflect the performance of the Company...
performance will affect the total capital of the company...which is the value... not by unit share price....kawan ray ooi...a company can issue another 1billion of new share,,, then u think the unit share price will dilute or?
go back and study the share market la... we need to see other than the profit after tax... there is a lot to consider when investing a share.... like the cash position... debt level... all that bla bla bla...
What Winson said is right lah, my friend. If u have bought, of course u can’t really accept those comment that bash down the counter. But I believe glove will be 1 last push by end of sept to really high price than before,normally 1 month earlier before the qr release. Then u will ride the momentum and make a good profit from its. After end of 2020 I will not enter glove counters anymore, because share market is acting forward looking 6 months earlier than the reality.
I told u d, glove counter will be 1 last push to really super high but not now so soon. Will be end of sept til early of October. I will take this as my last chance to big earn in glove counter. When the glove average selling price start dropping, no wonder how good for upcoming qr I will not enter anymore.
and if u say performance based... that is correct... then how about carepls? from from 5 to 3... in few days times... carepls is performing better also...
LYL is true after end of 2020, glove counter will be retracing back for sure. Share market is not a place to all in and all out bro. I did TP half of my holding week back then. Now batch by batch re-enter for the next wave. Beside I do think glove counter worth the price now in few years time. TP bankers give never for short term.
Yes there’s no way share price can go all the way up without correction. No banker will have ultimate cash to push. It’s good to see now foreign fund is coming back to absorb the shares banker throwing now. Soon bankers will have tons of cash in hand. And they will need to reinvest them. And high chance it would be glove counters.
ya... foreign fund coming in for the last few days....oversea market nis getting worse... malaysia consider still ok...mainly is covid... Malaysian did a good job back there...
Bankers can’t sell too fast as the price will shoot down too fast then their selling price won’t be looking good. Same as foreign fund, can’t collect too fast... Now is like push and pull, just wait and see. Haha 2 cents.
Winson yes for the price now Put warrant is a good hedging tool. I guess that’s what bankers thought too hahaha. Just see who can run faster. Hahahahaha
Yup..everyone have different opinion..there is no right or wrong
And sorry I will never all in no matter how confident I am for glove counter..it’s all about risk management!
i saw from my group discussion which i think it make sense la , banker is playing push n pull back , it purposely sell down to kill all those margin and contra player, and it will buy back which we cn c after the big drop thn it goes up slightly , lure those short term investors come back again , thn continue kill them all agn , and for now mostly all dying hopes, banker may continue plying all tis tricks tgt wif those news publish
Winson it’s not rising half year straight. Been gone through 2 big correction with many small corrections. But yes negative thoughts and comments keep coming when it’s drop. Money is yours, do your own risk management. Haha
Hahahaha mini 4 got impacted also bro. Comfort from RM4 retraced to Rm2.5, careplus from RM1.8 to below RM1. Ruberex same as comfort on June. Those HLT and so it’s because pure goreng with no fundamental and they are shoot up too fast and too high. Btw who knows, before that careplus also no fundamental.
I don't have any opinion whether gloves is sustainable or not. This is not something anyone can forecast reliably considering the very fluid situation of vaccines.
Near term, and I have look deeper into the trials of many vaccine makers, many have reported symptoms like fever, nausea which they dismissed as minor. I agree with the expert who written that these are not actually minor issues especially it has to be administered to millions and billions.
There will be a number of people who will have more extreme reaction than just fever nausea, and sore shoulder as reported by the Russian vaccine participants. The last week is dominated by vaccine news which to many is nothing more than just an extent of the arms race between major powers. Nothing concrete has taken place.
Back to gloves, many has expected a vaccine not to roll out till mid year, this has fueled the share price. If my analysis is correct, and the expected time line
Some have pointed out that during H1N1 there was alot of claims back and forth that they are so close to a vaccine. At last, it took much longer to materialised.